Cancer
-
Test identifies relapse risk among breast cancer patients
A low cost test could identify breast cancer patients who have an increased risk of relapse, according to the findings of a major clinical trial reported today. Read more
-
CA125 test better at predicting ovarian cancer
A readily available blood test is able to predict ovarian cancer risk more successfully than previously thought – particularly for the over 50s, according to newly published findings. Read more
-
Breast cancer and HRT risks evaluated
New estimates of the increased risks of breast cancer associated with different hormone replacement therapy preparations in the UK are published today. Read more
-
New generation BRAF inhibitor shows promise
A drug designed to work against a range of BRAF mutations in several cancers is showing early promise, a European conference heard last night. Read more
-
CRISPR/Cas9 pioneers win Nobel Prize
Two scientists whose work has revolutionised the treatment of haematological diseases have been awarded the Nobel Prize for Chemistry. Read more
-
Game changer’ paediatric neuroblastoma drug trial announced
A recently developed drug could be a “game changer” treatment for children with neuroblastoma, it was announced today. Read more
-
Treatment hope for HER2+ breast cancer patients
Women with early HER2+ breast cancer survive longer if they are prescribed lapatinib and trastuzumab before surgery, the results of a Spanish trial have revealed. Read more
-
How virus affected breast screening Europe-wide
The pressure on breast screening programmes across many European countries during the COVID-19 pandemic could lead to an increase in deaths from cancer, a conference will hear today. Read more
-
DNA repair drug benefits advanced cancer
A novel treatment for advanced cancer has shown promising results in a recent trial, British researchers have announced. Read more
-
Assessing treatment for older breast cancer patients
Many elderly breast cancer patients should be considered for more intensive treatment than is currently offered, researchers have found. Read more
